Experience of treatment of lung cancer patients using paclitaxel and carboplatin.
Nineteen patients with stage III & IV nonsmall cell lung cancer were treated with a regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina Central General Hospital, Jakarta, Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in 1 patient. Fourteen patients were in stage IV, 4 had stage IIIB, and one had stage IIIA disease. The regimen contained paclitaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 or AUC 6 mg/ml.min, given every 3 weeks. Those who underwent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (PR) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 17.5 months and 19 months after starting chemotherapy. The one-year survival rate was 58%, and median survival time was 14 months.
Jusuf
A
A
Dharmais National Cancer Center Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Mariono
S A
SA
Tambunan
K L
KL
Reksodiputro
A H
AH
Soetandyo
N
N
Hukom
R
R
Suratman
E
E
Jayusman
A M
AM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced
D016190:Carboplatin; D017239:Paclitaxel